Bullish Case: Momentum is real and falsifiable: CERT has gained 32.9% in 90 days and 11.7% in a month, driven by biosimulation/AI software adoption narrative. The 11/20 10.00 call (delta 0.43, the only liquid strike) shows call-side demand, and backwardated IV means near-term downside hedging is expensive relative to upside exposure—favoring call spreads. A Q3 bookings beat would squeeze an illiquid, under-owned stock quickly toward $12+.

Bearish Case: The term structure is backwardated (ATM ~149% Oct IV decaying to ~76% Aug 2027), signaling expected near-term event risk, and the Helium density peaks near $7.50, below spot. The stock is still -24% YoY and -74% over five years with a thin, unreliable options tape (most strikes show 400-500% IV and zero volume). Prior rebounds in 2026 stalled; a bookings miss or margin guide-down could erase the 90-day rally fast.

Potential Outcomes:

1. Consolidation $8.50-$10.50, ~40%: momentum fades into November earnings; Helium PDF mass at $7.50-$10 supports range.
2. Bookings-driven extension to $11-$13, ~25%: falsifiable via Q3 software bookings ≥5% QoQ; Nov 21 IV at 204% upper band prices this jump.
3. Mean-reversion decline to $6.50-$8, ~22%: falsifiable if bookings fall or SPY risk-off (SPY surface shows elevated downside-strike vol) hits a 24%-below-year-ago name.
4. M&A/strategic pop >+40%, ~8%: low valuation attracts consolidation bid.
5. Binary shock -40%+, ~5%: customer/regulatory loss in an illiquid tape.

Trading oracle: defined-risk Nov 10/12.50 call spreads on booking strength; avoid naked puts given 400%+ IV quotes—premiums are unreliably wide; consider waiting for IV crush post-earnings. Calibration note: my prior bearish calls (Feb-Aug) repeatedly overestimated downside—CERT instead rallied from $4.56 to $9.26; weight upside and consolidation higher now.

September 30, 2026